JP2015510913A5 - - Google Patents

Info

Publication number

JP2015510913A5

JP2015510913A5 JP2015500882A JP2015500882A JP2015510913A5 JP 2015510913 A5 JP2015510913 A5 JP 2015510913A5 JP 2015500882 A JP2015500882 A JP 2015500882A JP 2015500882 A JP2015500882 A JP 2015500882A JP 2015510913 A5 JP2015510913 A5 JP 2015510913A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

overweight

composition according

treating

patients diagnosed

Prior art date

2013-03-19

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 12
• 206010033307 Overweight Diseases 0.000 claims 9
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 5
• 208000008589 Obesity Diseases 0.000 claims 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
• 239000008103 glucose Substances 0.000 claims 5
• 235000020824 obesity Nutrition 0.000 claims 5
• 201000009104 prediabetes syndrome Diseases 0.000 claims 5
• 201000001421 hyperglycemia Diseases 0.000 claims 4
• 208000002705 Glucose Intolerance Diseases 0.000 claims 3
• 208000001145 Metabolic Syndrome Diseases 0.000 claims 3
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 3
• 230000005856 abnormality Effects 0.000 claims 3
• 210000000577 adipose tissue Anatomy 0.000 claims 3
• 239000000883 anti-obesity agent Substances 0.000 claims 3
• 229940125710 antiobesity agent Drugs 0.000 claims 3
• 239000008280 blood Substances 0.000 claims 3
• 210000004369 blood Anatomy 0.000 claims 3
• 208000035475 disorder Diseases 0.000 claims 3
• 208000024891 symptom Diseases 0.000 claims 3
• 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
• 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
• 208000001280 Prediabetic State Diseases 0.000 claims 2
• 230000037396 body weight Effects 0.000 claims 2
• 206010012601 diabetes mellitus Diseases 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 claims 2
• 229960003345 empagliflozin Drugs 0.000 claims 2
• 208000030159 metabolic disease Diseases 0.000 claims 2
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
• 206010002388 Angina unstable Diseases 0.000 claims 1
• 206010003210 Arteriosclerosis Diseases 0.000 claims 1
• PWDLDBWXTVILPC-WGAVTJJLSA-N CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 Chemical compound CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 PWDLDBWXTVILPC-WGAVTJJLSA-N 0.000 claims 1
• 208000031229 Cardiomyopathies Diseases 0.000 claims 1
• 208000002177 Cataract Diseases 0.000 claims 1
• 208000002249 Diabetes Complications Diseases 0.000 claims 1
• 208000032928 Dyslipidaemia Diseases 0.000 claims 1
• 102000017011 Glycated Hemoglobin A Human genes 0.000 claims 1
• 108010014663 Glycated Hemoglobin A Proteins 0.000 claims 1
• 206010019280 Heart failures Diseases 0.000 claims 1
• 206010022489 Insulin Resistance Diseases 0.000 claims 1
• 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
• YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims 1
• 108010019598 Liraglutide Proteins 0.000 claims 1
• 206010054805 Macroangiopathy Diseases 0.000 claims 1
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
• 208000017442 Retinal disease Diseases 0.000 claims 1
• 206010038923 Retinopathy Diseases 0.000 claims 1
• 208000007718 Stable Angina Diseases 0.000 claims 1
• 208000006011 Stroke Diseases 0.000 claims 1
• 208000007814 Unstable Angina Diseases 0.000 claims 1
• 230000002159 abnormal effect Effects 0.000 claims 1
• 238000009825 accumulation Methods 0.000 claims 1
• 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
• 229960001058 bupropion Drugs 0.000 claims 1
• 230000000747 cardiac effect Effects 0.000 claims 1
• 239000002552 dosage form Substances 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 230000002641 glycemic effect Effects 0.000 claims 1
• 230000035879 hyperinsulinaemia Effects 0.000 claims 1
• 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
• 201000008980 hyperinsulinism Diseases 0.000 claims 1
• 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
• 208000028867 ischemia Diseases 0.000 claims 1
• 208000017169 kidney disease Diseases 0.000 claims 1
• 229960002701 liraglutide Drugs 0.000 claims 1
• -1 lorcaserine Chemical compound 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 208000010125 myocardial infarction Diseases 0.000 claims 1
• DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 1
• 229960003086 naltrexone Drugs 0.000 claims 1
• 201000001119 neuropathy Diseases 0.000 claims 1
• 230000007823 neuropathy Effects 0.000 claims 1
• 208000033808 peripheral neuropathy Diseases 0.000 claims 1
• 230000000291 postprandial effect Effects 0.000 claims 1
• 230000001737 promoting effect Effects 0.000 claims 1
• 208000037803 restenosis Diseases 0.000 claims 1
• 230000033764 rhythmic process Effects 0.000 claims 1
• 229960004425 sibutramine Drugs 0.000 claims 1
• UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 1
• 210000001519 tissue Anatomy 0.000 claims 1
• 230000002792 vascular Effects 0.000 claims 1
• 230000004580 weight loss Effects 0.000 claims 1